Teva Pharmaceutical Industries Ltd. $TEVA Stock Position Increased by Amundi

Key Points

• Amundi increased its stake in Teva Pharmaceutical Industries by 18.5% during the first quarter, acquiring a total of 678,758 shares valued at approximately $10.08 million.
• Analysts are optimistic about TEVA shares, with multiple firms giving it a "buy" rating and setting a consensus target price of $24.71.
• Teva reported $0.66 EPS for the last quarter, exceeding estimates, but its revenue fell short of expectations at $4.18 billion.

Amundi lifted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 18.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 678,758 shares of the company's stock after acquiring an additional 105,846 shares during the period. Amundi owned 0.06% of Teva Pharmaceutical Industries worth $10,080,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 257.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 523,767 shares of the company's stock valued at $8,050,000 after buying an additional 377,096 shares during the period. Federation des caisses Desjardins du Quebec raised its holdings in shares of Teva Pharmaceutical Industries by 1.6% during the 1st quarter. Federation des caisses Desjardins du Quebec now owns 274,912 shares of the company's stock valued at $4,226,000 after buying an additional 4,416 shares during the period. Maverick Capital Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 114.0% during the 1st quarter. Maverick Capital Ltd. now owns 30,292 shares of the company's stock valued at $466,000 after buying an additional 16,137 shares during the period. Royal Bank of Canada raised its holdings in shares of Teva Pharmaceutical Industries by 0.4% during the 1st quarter. Royal Bank of Canada now owns 1,181,964 shares of the company's stock valued at $18,167,000 after buying an additional 4,361 shares during the period. Finally, Retirement Planning Co of New England Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 97.2% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 31,228 shares of the company's stock valued at $480,000 after buying an additional 15,393 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded up $0.07 during midday trading on Friday, reaching $19.96. 9,141,743 shares of the company traded hands, compared to its average volume of 9,876,074. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The firm has a market capitalization of $22.89 billion, a price-to-earnings ratio of -124.75, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The company has a fifty day moving average price of $17.31 and a 200 day moving average price of $16.50.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. During the same quarter in the previous year, the firm posted $0.61 EPS. The business's revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and an average target price of $24.71.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. This represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.49% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.